The PCWG3 Classification, published in 2016, updated and replaced the previously utilized PCWG2 guidelines (2008) for determining response in prostate cancer. The primary goals of the PCWG3 Classification were to improve prostate cancer patient evaluation and provide a broadly applicable approach to facilitate the comparison of patients and data for clinical trials as well as regulatory purposes.

Here we discuss the key features of PCWG3 and provide recommendations to operationalize this criterion in a clinical trial.